Reactive Oxygen Species and Antioxidants in Pulmonary Hypertension

Overview

Journal Antioxid Redox Signal

Specialty Endocrinology

Date 2012 Jun 5

PMID 22657091

Citations 49

Authors

Chi-Ming Wong

Geetanjali Bansal

Ludmila Pavlickova

Lucia Marcocci

Yuichiro J Suzuki

Affiliations

Soon will be listed here.

Abstract

Significance: Pulmonary hypertension is a devastating disorder without any available treatment strategies that satisfactorily promote the survival of patients. The identification of new therapeutic strategies to treat patients with pulmonary hypertension is warranted.

Recent Advances: Human studies have provided evidence that there is increased oxidative stress (lipid peroxidation, protein oxidation, DNA oxidation, and the depletion of small-molecule antioxidants) in patients with pulmonary hypertension. A variety of compounds with antioxidant properties have been shown to have beneficial therapeutic effects in animal models of pulmonary hypertension, possibly supporting the hypothesis that reactive oxygen species (ROS) are involved in the progression of pulmonary hypertension. Thus, understanding the molecular mechanisms of ROS actions could contribute to the development of optimal, antioxidant-based therapy for human pulmonary hypertension. One such mechanism includes action as a second messenger during cell-signaling events, leading to the growth of pulmonary vascular cells and right ventricular cells.

Critical Issues: The molecular mechanisms behind promotion of cell signaling for pulmonary vascular cell growth and right ventricular hypertrophy by ROS are not well understood. Evidence suggests that iron-catalyzed protein carbonylation may be involved.

Future Directions: Understanding precise mechanisms of ROS actions should be useful for designing preclinical animal experiments and human clinical trials of the use of antioxidants and/or other redox compounds in the treatment of pulmonary hypertension.

Citing Articles

Role of the Stress- and Inflammation-Induced Cytokine GDF-15 in Cardiovascular Diseases: From Basic Research to Clinical Relevance.

Schwarz A, Kinscherf R, Bonaterra G Rev Cardiovasc Med. 2024; 24(3):81.

PMID: 39077481 PMC: 11264000. DOI: 10.31083/j.rcm2403081.

Extrapulmonary manifestations of pulmonary arterial hypertension.

Singh N, Al-Naamani N, Brown M, Long G, Thenappan T, Umar S Expert Rev Respir Med. 2024; 18(3-4):189-205.

PMID: 38801029 PMC: 11713041. DOI: 10.1080/17476348.2024.2361037.

Potential Roles of Metals in the Pathogenesis of Pulmonary and Systemic Hypertension.

Hopkins C, Wessel C, Chen O, El-Kersh K, Cave M, Cai L Int J Biol Sci. 2023; 19(16):5036-5054.

PMID: 37928257 PMC: 10620830. DOI: 10.7150/ijbs.85590.

Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study.

Sanchez-Gloria J, Martinez-Olivares C, Del Valle-Mondragon L, Cortes-Camacho F, Zambrano-Vasquez O, Hernandez-Pando R Int J Mol Sci. 2023; 24(16).

PMID: 37629140 PMC: 10454707. DOI: 10.3390/ijms241612959.

Mitochondrial Dysfunction in Pulmonary Hypertension.

Ryanto G, Suraya R, Nagano T Antioxidants (Basel). 2023; 12(2).

PMID: 36829931 PMC: 9952650. DOI: 10.3390/antiox12020372.

References

Park A, Wong C, Jelinkova L, Liu L, Nagase H, Suzuki Y . Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension. 2010; 56(6):1145-51. PMC: 4157308. DOI: 10.1161/HYPERTENSIONAHA.110.160515. View

Nisbet R, Graves A, Kleinhenz D, Rupnow H, Reed A, Fan T . The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol. 2008; 40(5):601-9. PMC: 2677439. DOI: 10.1165/2008-0145OC. View

Lawrie A, Spiekerkoetter E, Martinez E, Ambartsumian N, Sheward W, MacLean M . Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005; 97(3):227-35. DOI: 10.1161/01.RES.0000176025.57706.1e. View

Kamezaki F, Tasaki H, Yamashita K, Tsutsui M, Koide S, Nakata S . Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 2007; 177(2):219-26. DOI: 10.1164/rccm.200702-264OC. View

Liu Y, Suzuki Y, Day R, Fanburg B . Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res. 2004; 95(6):579-86. DOI: 10.1161/01.RES.0000141428.53262.a4. View

Liu L, Marcocci L, Wong C, Park A, Suzuki Y . Serotonin-mediated protein carbonylation in the right heart. Free Radic Biol Med. 2008; 45(6):847-54. PMC: 2574542. DOI: 10.1016/j.freeradbiomed.2008.06.008. View

Lakshminrusimha S, Russell J, Wedgwood S, Gugino S, Kazzaz J, Davis J . Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174(12):1370-7. PMC: 2111046. DOI: 10.1164/rccm.200605-676OC. View

Suzuki Y, Forman H, Sevanian A . Oxidants as stimulators of signal transduction. Free Radic Biol Med. 1997; 22(1-2):269-85. DOI: 10.1016/s0891-5849(96)00275-4. View

Headlam H, Davies M . Beta-scission of side-chain alkoxyl radicals on peptides and proteins results in the loss of side-chains as aldehydes and ketones. Free Radic Biol Med. 2002; 32(11):1171-84. DOI: 10.1016/s0891-5849(02)00814-6. View

10.

Wedgwood S, Dettman R, Black S . ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol. 2001; 281(5):L1058-67. DOI: 10.1152/ajplung.2001.281.5.L1058. View

11.

Berlett B, Stadtman E . Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997; 272(33):20313-6. DOI: 10.1074/jbc.272.33.20313. View

12.

Grobe A, Wells S, Benavidez E, Oishi P, Azakie A, Fineman J . Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. Am J Physiol Lung Cell Mol Physiol. 2006; 290(6):L1069-77. DOI: 10.1152/ajplung.00408.2005. View

13.

Wong C, Cheema A, Zhang L, Suzuki Y . Protein carbonylation as a novel mechanism in redox signaling. Circ Res. 2007; 102(3):310-8. DOI: 10.1161/CIRCRESAHA.107.159814. View

14.

Jankov R, Kantores C, Pan J, Belik J . Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2007; 294(2):L233-45. DOI: 10.1152/ajplung.00166.2007. View

15.

Amici A, Levine R, Tsai L, Stadtman E . Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem. 1989; 264(6):3341-6. View

16.

Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C . Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985). 2001; 90(4):1299-306. DOI: 10.1152/jappl.2001.90.4.1299. View

17.

Lachmanova V, Hnilickova O, Povysilova V, Hampl V, Herget J . N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci. 2005; 77(2):175-82. DOI: 10.1016/j.lfs.2004.11.027. View

18.

Csiszar A, Labinskyy N, Olson S, Pinto J, Gupte S, Wu J . Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009; 54(3):668-75. PMC: 2745434. DOI: 10.1161/HYPERTENSIONAHA.109.133397. View

19.

Suzuki Y, Day R, Tan C, Sandven T, Liang Q, Molkentin J . Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J Biol Chem. 2003; 278(19):17525-31. DOI: 10.1074/jbc.M210465200. View

20.

Bowers R, Cool C, Murphy R, Tuder R, Hopken M, Flores S . Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med. 2004; 169(6):764-9. DOI: 10.1164/rccm.200301-147OC. View